Lung Cancer Clinical Trial

Combined Modality Treatment for Resectable Non-Small Cell Superior Sulcus Tumors

Summary

To determine the outcome of patients with potentially resectable superior sulcus tumors of non-small cell histology treated by surgery followed by accelerated radiation therapy and chemotherapy.
To evaluate toxicity, the initial local-regional control rate, sites of and time to local and distant failures.

View Full Description

Full Description

Eligible (surgically resectable and medically operable) patients will have surgery followed by radiation therapy, given twice daily, for 5 weeks if margins are negative and for 5-1/2 weeks for positive margins. Grossly positive margins can be treated by brachytherapy followed by external radiotherapy.

Concomitant chemotherapy consisting of cisplatin given intravenously on days 1 and 8, and etoposide taken by mouth 30-60 minutes prior to each radiotherapy treatment x the first 10 days. The cycle will be repeated start day 29.

If the patients are considered to have no evidence of disease in one month after completion of chemotherapy, optional prophylactic radiotherapy to the brain will be give in 10 fractions once daily for 2 weeks.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

No previous treatment.
Tumor must be resectable.
>/= 18 and Zubrod performance status Must have adequate bone marrow, liver and renal function as defined in 3.6.

Exclusion Criteria:

Cytological or histological proof of N3 disease.
Evidence of metastatic disease to distant sites.
Patients with impending cord compression will be ineligible.

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

38

Study ID:

NCT00984997

Recruitment Status:

Completed

Sponsor:

M.D. Anderson Cancer Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

University of Texas MD Anderson Cancer Center
Houston Texas, 77030, United States

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

38

Study ID:

NCT00984997

Recruitment Status:

Completed

Sponsor:


M.D. Anderson Cancer Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider